Residency · Residency · Cardiology

Mitral Regurgitation: Primary vs. Secondary

Anatomy and Mechanism Classification

Mitral Valve Apparatus

The mitral valve apparatus consists of five interdependent components whose coordinated function is required for competent valve closure. The anterior leaflet is divided into segments A1, A2, and A3, while the posterior leaflet comprises P1, P2, and P3 segments. The annulus has a saddle-shaped fibrous-muscular configuration. The chordae tendineae are classified as primary or marginal chordae, secondary or strut chordae, and tertiary or basal chordae. The papillary muscles include the anterolateral papillary muscle, which receives a dual blood supply from the left anterior descending and left circumflex arteries, and the posteromedial papillary muscle, which has a single blood supply from the posterior descending artery or right coronary artery, making it more vulnerable to ischemic injury.

Carpentier Functional Classification

The Carpentier classification provides the framework for understanding mitral regurgitation mechanisms. Type I is characterized by normal leaflet motion with regurgitation caused by annular dilation or leaflet perforation from endocarditis, producing a central regurgitant jet. Type II involves excessive leaflet motion due to prolapse or flail from chordal elongation or rupture, with the jet directed away from the prolapsing leaflet. Type IIIa features restricted leaflet motion in both systole and diastole, typical of rheumatic disease with commissural fusion and leaflet thickening. Type IIIb involves restricted leaflet motion in systole only, caused by functional or secondary MR from left ventricular dilation that tethers the leaflets apically.

Primary (Organic/Degenerative) MR

Primary mitral regurgitation results from intrinsic structural abnormalities of the valve apparatus. Myxomatous degeneration, or Barlow disease, produces diffuse thickening with redundant tissue and multiple segment involvement, typically affecting younger patients. Fibroelastic deficiency presents with single-segment prolapse or flail, most commonly involving the P2 segment, in older patients with thinner leaflets. Flail leaflet from ruptured chordae causes the leaflet tip to evert into the left atrium during systole, producing acute severe mitral regurgitation. Rheumatic disease causes thickened, retracted leaflets with commissural fusion, often producing mixed stenosis and regurgitation. Endocarditis may cause leaflet perforation or vegetation-related MR with chordal destruction. Connective tissue disorders including Marfan syndrome, Ehlers-Danlos syndrome, and osteogenesis imperfecta are associated with mitral valve prolapse and annular dilation.

Secondary (Functional) MR

Secondary mitral regurgitation involves a structurally normal valve with regurgitation caused by left ventricular remodeling and dysfunction. Ischemic secondary MR typically results from inferoposterior myocardial infarction causing asymmetric tethering of the posterior leaflet through displacement of the posteromedial papillary muscle, with the jet typically directed posteriorly. This may be acute, as in papillary muscle rupture, or chronic. Non-ischemic secondary MR from dilated cardiomyopathy results from global left ventricular dilation producing symmetric leaflet tethering and annular dilation, with a characteristically central jet.

Echocardiographic Assessment of Severity

Qualitative Parameters

Color Doppler jet area is unreliable as a sole marker of severity because it is affected by loading conditions, jet eccentricity, and instrument settings. The Coanda effect causes wall-hugging eccentric jets to appear smaller than their true severity. Vena contracta, the narrowest neck of the regurgitant jet, is measured in the parasternal long-axis or apical views perpendicular to the commissural line, with a value of 7 mm or greater indicating severe regurgitation. Continuous-wave Doppler signal density provides qualitative guidance, with a dense, triangular envelope with early peak suggesting severe MR and a faint signal suggesting mild disease. Flow convergence proximal to the regurgitant orifice, or PISA, visible at a Nyquist limit of 30 to 40 cm/s, suggests at least moderate MR.

Quantitative Parameters (PISA Method)

The effective regurgitant orifice area is calculated as two times pi times the PISA radius squared times the aliasing velocity, divided by the peak MR velocity. Regurgitant volume equals the EROA multiplied by the MR VTI. For primary MR, the severity thresholds are EROA of 0.40 cm^2 or greater, regurgitant volume of 60 mL or greater, and regurgitant fraction of 50% or greater. For secondary MR, the thresholds are intentionally lower at EROA of 0.20 cm^2 or greater and regurgitant volume of 30 mL or greater, reflecting the fact that the diseased left ventricle cannot tolerate even moderate regurgitant volumes, resulting in worse prognosis at lower regurgitant volumes.

3D Echocardiography

Three-dimensional vena contracta area, obtained through direct planimetry of the regurgitant orifice, represents the most accurate single measurement. Severe thresholds are 0.41 cm^2 or greater for primary MR and 0.20 cm^2 or greater for secondary MR. Three-dimensional color Doppler overcomes the geometric assumptions inherent in two-dimensional PISA, which assumes a hemispheric convergence zone that is often elliptical in secondary MR. The 3D en face "surgical view" of the mitral valve from the left atrial side enables precise localization of prolapse for surgical planning.

Supportive Findings

Pulmonary vein flow reversal in systole, detected in one or more pulmonary veins using pulsed-wave Doppler, suggests severe MR. Mitral inflow demonstrates E-wave dominance with an E/A ratio exceeding 1.5 and elevated E velocity above 1.2 m/s in chronic severe MR. Left atrial dilation above 55 mL/m^2 reflects chronic volume overload. Left ventricular dilation with an LVEDD above 65 mm indicates significant volume overload in chronic severe primary MR. Elevated pulmonary artery systolic pressure, estimated from tricuspid regurgitation velocity, provides further hemodynamic assessment.

<image> A comparison illustration of primary vs. secondary mitral regurgitation mechanisms. Two side-by-side long-axis heart cross-sections. Left panel labeled "Primary MR (P2 Prolapse/Flail)": shows a structurally abnormal posterior leaflet (P2 segment) with ruptured chordae, the leaflet tip flailing into the LA during systole. The MR jet (shown in blue/mosaic color) is directed anteriorly (away from the prolapsing posterior leaflet) and is eccentric, hugging the anterior LA wall (Coanda effect). The LV is normal or hyperdynamic. A small inset shows the TEE en face view with the prolapsing P2 segment highlighted in red. Right panel labeled "Secondary MR (Ischemic)": shows a structurally normal valve with the posteromedial papillary muscle displaced apically and laterally due to inferior LV wall motion abnormality. Tethering forces pull the posterior leaflet apically, preventing coaptation. The MR jet is directed posteriorly. The annulus is dilated. The LV is dilated with thinning and akinesis of the inferior wall (scar shown in gray). Annotations: coaptation depth, tenting area, and annular diameter labeled on both panels. Key differences highlighted in text boxes below each panel. </image>

Primary MR: Management

Indications for Surgery

Symptomatic severe primary MR carries a Class I indication for mitral valve surgery, with repair preferred over replacement. Asymptomatic severe primary MR with left ventricular dysfunction, defined by an LVEF of 60% or below or an LVESD of 40 mm or greater, also carries a Class I indication, as these thresholds represent early ventricular decompensation and further delay risks irreversible left ventricular damage. For asymptomatic severe primary MR with preserved left ventricular function, surgery should be considered as a Class IIa recommendation when there is a high likelihood of successful repair exceeding 95% at an experienced center, new-onset atrial fibrillation, resting pulmonary artery systolic pressure exceeding 50 mmHg, progressive left ventricular dilation with LVESD of 37 to 39 mm, declining ejection fraction trending between 60 and 65%, or a flail leaflet with EROA of 0.40 cm^2 or greater due to the high event rate. Exercise testing can unmask occult symptoms, and exercise-induced pulmonary hypertension with PASP exceeding 60 mmHg supports earlier intervention.

Mitral Valve Repair vs. Replacement

Repair is preferred over replacement in primary MR because it offers lower operative mortality of less than 1% compared to 3 to 5% for replacement, better long-term survival, and avoidance of prosthetic valve complications. Repair durability is excellent, with greater than 90% freedom from reoperation at 20 years for posterior leaflet prolapse, though anterior leaflet and bileaflet repair are less durable. Standard repair techniques include triangular or quadrangular resection of the prolapsing segment, neochordae using Gore-Tex artificial chordae, edge-to-edge repair with the Alfieri stitch, and annuloplasty ring placement, which is an essential component of all repairs. Repair feasibility is most favorable with isolated P2 prolapse, fibroelastic deficiency pathology, and an experienced surgeon performing 25 or more mitral valve repairs per year. Repair is less favorable with extensive Barlow disease, severe annular calcification, anterior leaflet prolapse, or active endocarditis with tissue destruction. Replacement is indicated for unfavorable anatomy for repair, rheumatic MR, failed repair, or endocarditis with extensive destruction, with preservation of the subvalvular apparatus whenever possible.

Transcatheter Edge-to-Edge Repair (TEER) for Primary MR

MitraClip and PASCAL devices approximate the anterior and posterior leaflets to create a double orifice. The EVEREST II trial demonstrated that MitraClip in primary MR was less effective than surgery at reducing MR, with residual MR more common, but was safer with fewer complications. The role of TEER in primary MR is limited to high or prohibitive surgical risk patients after heart team discussion, provided anatomic suitability criteria are met, including adequate leaflet length, coaptation depth below 11 mm, flail gap below 10 mm, and flail width below 15 mm.

Secondary MR: Management

Medical Optimization First

Guideline-directed medical therapy for heart failure with reduced ejection fraction, encompassing all four medication pillars, may reduce secondary MR by promoting reverse remodeling. Cardiac resynchronization therapy in appropriate candidates with left bundle branch block and ejection fraction of 35% or below can reduce functional MR through resynchronization of papillary muscle contraction and reverse remodeling. Up to 30% of patients with secondary MR will experience significant improvement with optimized medical therapy and CRT.

TEER for Secondary MR

The COAPT trial demonstrated that MitraClip combined with guideline-directed medical therapy, compared with medical therapy alone, in patients with heart failure with reduced ejection fraction (EF 20 to 50%) and moderate-to-severe or severe secondary MR (EROA of 0.30 cm^2 or greater) despite maximal medical therapy, reduced heart failure hospitalizations by 47% and all-cause mortality by 29% at 2 years, with benefit sustained at 5 years. The MITRA-FR trial found no benefit of MitraClip in secondary MR. The key difference lies in the concept of proportionate versus disproportionate MR: COAPT enrolled patients with disproportionately severe MR relative to their left ventricular size (EROA of 0.30 cm^2 or greater), while MITRA-FR enrolled patients with proportionate MR (EROA of 0.20 cm^2 or greater) on potentially suboptimal medical therapy. COAPT eligibility criteria include ejection fraction of 20 to 50%, LVESD below 70 mm, EROA of 0.30 cm^2 or greater, maximally tolerated guideline-directed medical therapy, heart team review, and symptomatic NYHA Class II to IV heart failure. The key principle is to select patients in whom the valve disease makes an independent contribution to the heart failure syndrome.

Surgical Intervention for Secondary MR

The CTSN trial comparing mitral valve repair with restrictive annuloplasty versus replacement in severe ischemic MR demonstrated that replacement was superior to repair at 2 years, driven by a 58% MR recurrence rate after repair, though there was no mortality difference. For moderate ischemic MR, the CTSN trial of adding MV repair to CABG showed no improvement in outcomes compared to CABG alone at 2 years, as reverse remodeling occurs with revascularization. The current approach favors CABG alone for moderate secondary MR, with mitral valve intervention through replacement or repair considered when severe secondary MR is present at the time of CABG.

Acute Severe Mitral Regurgitation

Etiologies

Papillary muscle rupture following myocardial infarction causes acute hemodynamic collapse, with partial rupture of the papillary head more common than complete rupture. The posteromedial papillary muscle is most commonly affected due to its single blood supply. Chordal rupture from myxomatous degeneration produces sudden-onset dyspnea and flash pulmonary edema. Endocarditis may cause leaflet perforation or vegetation-induced flail. Prosthetic valve dehiscence creates paravalvular leak after mitral valve replacement.

Presentation and Diagnosis

Acute severe MR presents with pulmonary edema and cardiogenic shock. The classic systolic murmur may be soft or absent due to rapid pressure equalization between the left ventricle and left atrium. Echocardiography demonstrates a flail leaflet or ruptured papillary muscle with a severe eccentric MR jet, while the left atrium may be normal in size as there has been insufficient time for remodeling. Hemodynamic monitoring reveals tall V waves on the pulmonary capillary wedge pressure tracing, potentially exceeding 50 to 60 mmHg. Emergent surgery is required, with medical stabilization as a bridge using afterload reduction with nitroprusside if blood pressure allows, intra-aortic balloon pump, and inotropes.

<image> A clinical management algorithm for mitral regurgitation. Start with "Significant MR Detected on Echo" at top, branching into "Primary MR" (left) and "Secondary MR" (right). Primary MR branch: "Severe? (EROA >= 0.40 cm^2, RVol >= 60 mL, VC >= 7 mm)" → if yes: "Symptomatic or LV dysfunction (EF <= 60% or LVESD >= 40mm)?" → if yes: "MV Surgery: Repair preferred over replacement at experienced center." If asymptomatic with preserved LV: "Consider surgery if: high repair likelihood (>95%), new AF, PASP >50, progressive LV dilation; otherwise serial monitoring q6-12 months." If high surgical risk: "Consider TEER if anatomically suitable." Secondary MR branch: "Optimize GDMT (4 pillars) + CRT if indicated" → "Reassess MR severity after 3 months optimization" → if persistent severe MR (EROA >= 0.30 cm^2): "COAPT-eligible? (EF 20-50%, LVESD <70mm, on max GDMT)" → if yes: "TEER (MitraClip/PASCAL)." If surgical candidate needing CABG: "Consider MV intervention at time of CABG if severe MR." Use green for primary MR pathway, orange for secondary MR pathway, red for emergent surgery in acute MR (separate small box in corner). </image>

Key Clinical Pearls

• In primary MR, the LVESD >= 40 mm and EF <= 60% thresholds represent early LV decompensation -- the normal LV response to chronic volume overload is hyperdynamic (EF > 60%); an "normal" EF of 55% in severe MR actually represents subclinical LV dysfunction
• Eccentric MR jets (Coanda effect) appear smaller on color Doppler than central jets of equivalent severity -- always use quantitative methods (PISA, vena contracta, 3D VCA) for eccentric jets, especially in primary MR with prolapse
• The COAPT vs. MITRA-FR discrepancy is best explained by proportionate vs. disproportionate MR: MitraClip benefits patients whose MR severity is OUT OF PROPORTION to their LV dilation -- if MR is simply a consequence of a very dilated LV, fixing the valve alone is insufficient
• In acute severe MR, the classic systolic murmur may be soft or absent due to rapid pressure equalization between LV and LA -- do not rely on auscultation to diagnose or exclude acute MR
• MV repair referral should be to experienced centers with documented repair rates > 95% and mortality < 1% for posterior leaflet prolapse -- center volume and surgeon experience directly impact outcomes
• Secondary MR severity thresholds are intentionally LOWER than primary MR (EROA >= 0.20 cm^2 vs >= 0.40 cm^2) because the diseased LV cannot tolerate even moderate regurgitant volumes

References

• Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease. Circulation. 2021;143:e72-e227.
• Stone GW, et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure (COAPT). NEJM. 2018;379:2307-2318.
• Obadia JF, et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation (MITRA-FR). NEJM. 2018;379:2297-2306.
• Goldstein D, et al. Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation (CTSN). NEJM. 2016;374:344-353.
• Zoghbi WA, et al. Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation. J Am Soc Echocardiogr. 2017;30:303-371.

Read this lecture as Markdown